BB3008

Primary objectives: (1) To evaluate the safety and tolerability of different doses of BB3008 tablets as a monotherapy in subjects with advanced solid tumors, determine the MTD of BB3008 tablets, and provide a basis for the determination of RP2D; Secondary objectives: (1) To evaluate the PK characteristics of BB3008 tablets in subjects with advanced solid tumors; (2) To preliminarily evaluate the efficacy of BB3008 tablets as a monotherapy in subjects with advanced solid tumors; (3) To preliminarily identify the metabolites of BB3008 in patients with advanced solid tumors (if any); Exploratory objectives: (1) To explore biomarkers related to the efficacy and safety of BB3008; (2) To explore the correlation between blood drug concentration and Fridericia-corrected QT interval (QTcF) (C-QTcF analysis).